Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $10.00. The company’s shares opened today at $1.80.
Rahimi covers the Healthcare sector, focusing on stocks such as Prothena, Crinetics Pharmaceuticals, and Chinook Therapeutics. According to TipRanks, Rahimi has an average return of 7.6% and a 37.93% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexicon Pharmaceuticals with a $8.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.79 and a one-year low of $1.71. Currently, Lexicon Pharmaceuticals has an average volume of 2.64M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LXRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Read More on LXRX:
- Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- LXRX Upcoming Earnings Report: What to Expect?
- Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
- Lexicon appoints Sullivan to board of directors
- Lexicon Elects Diane E. Sullivan to Board of Directors
